Based upon our experience, we have been able to identify certain cannabinoid and terpene profiles that are targeted to specific outcomes.
Part of our terpene enriched collection, this formulation contains Linalool, which can also be found in lavender, peanut stems and leaves.
Current research indicates that Linalool blocks the receptors for the primary excitatory brain chemical glutamate. Mice exposed to Linalool vapors in an animal study showed reduced levels of anxiety and lower depressed behaviors.
Part of our strain collection, this formulation is enriched with a terpene combination of B-caryophyllene, Limonene and Humulene. It is modeled after the GSC strain..
Research suggests that B-caryophyllene may be able to help manage symptoms associated with anxiety and depression.
Part of our Cold Press Collection, this formulation contains 50% CBDa and 50% CBD.
Cannabidiolic acid (CBDa) is a non-psychoactive cannabinoid found in the hemp plant. CBDa is sourced by raw processing of the cannabis sativa L hemp plant, and is the precursor to CBD. Through a heating process called decarboxylation, CBDa is converted to CBD when it reaches 230° F. CBDa is widely considered to be a key constituent in the medicinal spectrum of cannabis. CBDa has been shown to reduce depression-like behavior in animal models.
We highly recommend speaking with your doctor before using CBD. This is especially important if you are taking medications. You may also contact our nurse line.